The Importance of Dose-Intensity in Neoadjuvant Chemotherapy of Osteosarcoma: A retrospective analysis of high-dose methotrexate, cisplatinum and adriamycin used preoperatively
- 1 April 1990
- journal article
- research article
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 2 (2) , 127-135
Abstract
The relationship between dose-intensity and outcome was retrospectively analyzed in 125 patients with osteosarcoma of the extremities treated at our institution with neoadjuvant chemotherapy between 1986 and 1988. Before surgery, chemotherapy was performed with high-dose methotrexate (HDMTX) i.v. followed by cisplatinum (CDP) i.a. and adriamycin (ADM) i.v. Postoperative chemotherapy was tailored according to the necrosis induced by preoperative treatment. Patients who were «good responders» had 31-weeks of chemotherapy with the same drugs utilized preoperatively, while «poor responder» patients received a longer treatment (40 weeks) in which ifosfamide and etoposide (VP-16) were added to HDMTX, CDP and ADM. At a median follow-up of 2 years (1-3 years) 100 patients (80%) remained continuously disease-free and 25 patients relapsed: 24 with lung metastases and 1 with local recurrence. According to the real dose-intensity received, calculated as a percentage of the dose intensity projected by the protocol, the continuously disease-free survival was 87% in the 82 patients who received 80% or more of the scheduled dose-intensity and only 65% for the 43 patients who received less than 80% of the projected dose-intensity. This difference is highly significant (P < 0.01). These results suggest that in neoadjuvant chemotherapy of osteosarcoma the real dose-intensity delivered is a determinant of treatment outcome and therefore every effort should be made to avoid reductions of doses and delays of cycles of chemotherapy in these patients.Keywords
This publication has 9 references indexed in Scilit:
- Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response.Journal of Clinical Oncology, 1988
- Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer.Journal of Clinical Oncology, 1986
- The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the ExtremityNew England Journal of Medicine, 1986
- Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy regional mapping of viable and nonviable tumorCancer, 1985
- Preoperative (Neoadjuvant) Chemotherapy for Osteogenic Sarcoma: A Ten Year ExperienceOrthopedics, 1985
- The importance of dose intensity in chemotherapy of metastatic breast cancer.Journal of Clinical Oncology, 1984
- Dose-Response Effect of Adjuvant Chemotherapy in Breast CancerNew England Journal of Medicine, 1981
- A System for the Surgical Staging of Musculoskeletal SarcomaClinical Orthopaedics and Related Research, 1980
- Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease.British Journal of Clinical Pharmacology, 1980